Trial · NCT02502487
Dorsal Penile Nerve Block for Rigid Cystoscopy in Men
NCT02502487, Not applicable, Completed, West China Hospital; results first posted 2016-07-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dorsal Penile Nerve Block for Rigid Cystoscopy in Men. Trials, record NCT02502487. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02502487
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dorsal Penile Nerve Block for Rigid Cystoscopy in Men
- NCT number
- NCT02502487
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 258 participants, actual
- Lead sponsor
- West China Hospital
- Conditions
- Pain
- Interventions
- Dorsal Penile Nerve Block, Ropivacaine, Tetracaine
- First posted
- 2015-07-20
- Last updated
- 2020-03-31
- Results first posted
- 2016-07-11
- Limitations and caveats
- The VAS scale was the only main observe index, and patients could have different cognition of pain and this may affect the evaluation of pain.
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of external sphincter | A visual analog scale (VAS) ranging from 0 to 10 was used to assess the patients' pain during the procedure. 0 means no pain, 1 to 3 means mild pain, 4 to 7 means moderate pain, and 8 to 10 means severe pain. Patients were asked the VAS score to express the degree of pain at each time point. |
| Secondary | Visual Analog Scale (VAS) for Pain | before gel administration | A visual analog scale (VAS) ranging from 0 to 10 was used to assess the patients' pain during the procedure. 0 means no pain, 1 to 3 means mild pain, 4 to 7 means moderate pain, and 8 to 10 means severe pain. Patients were asked the VAS score to express the degree of pain at each time point. |
| Secondary | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of penile and bulbar urethra | A visual analog scale (VAS) ranging from 0 to 10 was used to assess the patients' pain during the procedure. 0 means no pain, 1 to 3 means mild pain, 4 to 7 means moderate pain, and 8 to 10 means severe pain. Patients were asked the VAS score to express the degree of pain at each time point. |
| Secondary | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of prostate and bladder | A visual analog scale (VAS) ranging from 0 to 10 was used to assess the patients' pain during the procedure. 0 means no pain, 1 to 3 means mild pain, 4 to 7 means moderate pain, and 8 to 10 means severe pain. Patients were asked the VAS score to express the degree of pain at each time point. |
| Secondary | Visual Analog Scale (VAS) for Pain | after withdrawal of cystoscope | A visual analog scale (VAS) ranging from 0 to 10 was used to assess the patients' pain during the procedure. 0 means no pain, 1 to 3 means mild pain, 4 to 7 means moderate pain, and 8 to 10 means severe pain. Patients were asked the VAS score to express the degree of pain at each time point. |
| Secondary | Heart Rate Before Gel Administration | before gel administration | |
| Secondary | Heart Rate at Cystoscopic Inspection of Penile and Bulbar Urthra | at cystoscopic inspection of penile and bulbar urethra | |
| Secondary | Heart Rate at Cystoscopic Inspection of External Sphincter | at cystoscopic inspection of external sphincter | |
| Secondary | Heart Rate After Withdrawal of Cystoscope | after withdrawal of cystoscope | |
| Secondary | Mean Arterial Pressure Before Gel Administration | before gel administration |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of external sphincter | units on a scale | MEDIAN | |
| SECONDARY | Visual Analog Scale (VAS) for Pain | before gel administration | units on a scale | MEDIAN | |
| SECONDARY | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of penile and bulbar urethra | units on a scale | MEDIAN | |
| SECONDARY | Visual Analog Scale (VAS) for Pain | at cystoscopic inspection of prostate and bladder | units on a scale | MEDIAN | |
| SECONDARY | Visual Analog Scale (VAS) for Pain | after withdrawal of cystoscope | units on a scale | MEDIAN | |
| SECONDARY | Heart Rate Before Gel Administration | before gel administration | Beats per minute | MEAN | |
| SECONDARY | Heart Rate at Cystoscopic Inspection of Penile and Bulbar Urthra | at cystoscopic inspection of penile and bulbar urethra | Beats per minute | MEAN | |
| SECONDARY | Heart Rate at Cystoscopic Inspection of External Sphincter | at cystoscopic inspection of external sphincter | Beats per minute | MEAN | |
| SECONDARY | Heart Rate After Withdrawal of Cystoscope | after withdrawal of cystoscope | Beats per minute | MEAN | |
| SECONDARY | Mean Arterial Pressure Before Gel Administration | before gel administration | mmHg | MEAN |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Visual Analog Scale (VAS) for Pain | Tetracaine Gel Group | 6 | Inter-Quartile Range 5 to 7 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Dorsal Penile Nerve Block Group | 4 | Inter-Quartile Range 3 to 6 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Combination Group | 4 | Inter-Quartile Range 3 to 5 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Tetracaine Gel Group | 0 | Inter-Quartile Range 0 to 0 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Dorsal Penile Nerve Block Group | 0 | Inter-Quartile Range 0 to 0 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Combination Group | 0 | Inter-Quartile Range 0 to 0 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Tetracaine Gel Group | 1 | Inter-Quartile Range 1 to 2 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Dorsal Penile Nerve Block Group | 1 | Inter-Quartile Range 1 to 2 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Combination Group | 1 | Inter-Quartile Range 1 to 1 | units on a scale | |
| Visual Analog Scale (VAS) for Pain | Tetracaine Gel Group | 2 | Inter-Quartile Range 0 to 2 | units on a scale |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tetracaine Gel Group | 86 | |
| Overall Study | STARTED | Dorsal Penile Nerve Block Group | 86 | |
| Overall Study | STARTED | Combination Group | 86 | |
| Overall Study | COMPLETED | Tetracaine Gel Group | 86 | |
| Overall Study | COMPLETED | Dorsal Penile Nerve Block Group | 86 | |
| Overall Study | COMPLETED | Combination Group | 86 | |
| Overall Study | NOT COMPLETED | Tetracaine Gel Group | 0 | |
| Overall Study | NOT COMPLETED | Dorsal Penile Nerve Block Group | 0 | |
| Overall Study | NOT COMPLETED | Combination Group | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tetracaine Group | ||
| Total, all-cause mortality | DPNB Group | ||
| Total, all-cause mortality | Combination Group | ||
| Total, other adverse events | Tetracaine Group | 0 | 86 |
| Total, other adverse events | DPNB Group | 0 | 86 |
| Total, other adverse events | Combination Group | 0 | 86 |
| Total, serious adverse events | Tetracaine Group | 0 | 86 |
| Total, serious adverse events | DPNB Group | 0 | 86 |
| Total, serious adverse events | Combination Group | 0 | 86 |
Source ClinicalTrials.gov
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02502487
GET https://conductscience.org/api/trials/v1/NCT02502487/registered?page=2